Tag: Cancer: Skin
Chronic Adverse Effects From Anti-PD-1 Immunotherapies Common
About 43 percent of patients who receive anti-PD1 therapy for advanced melanoma have chronic immune-related adverse effects
Fecal Transplant May Counter Anti-PD-1 Resistance in Melanoma
FMT plus anti-PD-1 therapy may change gut microbiome and help overcome drug resistance in some patients with advanced melanoma
Biomarker May Predict Treatment Outcome in Advanced Melanoma
Changes in plasma levels of ctDNA associated with survival outcomes in BRAF V600 mutation-positive unresectable or metastatic melanoma
ICI Need Not Be Withheld in Those With Autoimmune Disease
Objective response rates to anti-CTL4, anti-PD-1, combination similar for advanced melanoma patients with, without AID
Immune Checkpoint Inhibitor Therapy Tied to Cardiac Event Risk
Increased risks persist beyond six months for patients with lung cancer receiving PD1i and with malignant melanoma receiving CTLA-4i
UV Exposure Not Linked to Risk for Melanoma in Skin of Color
In 11 of 13 studies reviewed, no association observed between UV exposure, melanoma in skin of color
AI Model May Predict Immunotherapy Response in Melanoma
Histology slides, clinical data used to predict immune checkpoint inhibitor response in advanced melanoma
Benefit of Adjuvant Dabrafenib + Trametinib Persists in Melanoma
Follow-up Calls After Mohs Surgery Do Not Boost Satisfaction
